Safety and experience

1.png

Clinical trials and extensive real-world experience demonstrated that Fluad has a safety profile similar to that of other seasonal flu vaccines in those aged 65 years and older.1,2

 
 
Untitled-22.png

Vaccination with Fluad is associated with more local and systemic reactions than with other seasonal flu vaccines including headache, local site reactions and fatigue.

These are usually mild to moderate and typically resolve within 3 days.1,2

 
 
Untitled-23.png
 

Approved in New Zealand, Australia, UK, EU, US, Canada and other countries. Nearly 144 million doses of Fluad TIV have been distributed worldwide for over 20 years.3

In Australia, Fluad is the fully funded vaccine for all people aged 65 years and older.

 
 

Reference: 1. Seqirus NZ. FLUAD Data Sheet. Seqirus (NZ) Ltd. January 2020. 2. Lapi F, Marconi E, Simonetti M, et al. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly. Expert Rev Vaccines. 2019 Jun;18(6):663-670. 3. Data on file. Seqirus Inc; 2020.